Johnson Investment Counsel Inc. Decreases Position in Sanofi (NASDAQ:SNY)

Johnson Investment Counsel Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 3.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,259 shares of the company’s stock after selling 312 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Sanofi were worth $498,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. LPL Financial LLC lifted its stake in Sanofi by 23.9% in the second quarter. LPL Financial LLC now owns 1,082,559 shares of the company’s stock valued at $52,526,000 after buying an additional 208,984 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Sanofi by 3.9% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 23,601 shares of the company’s stock valued at $1,145,000 after buying an additional 886 shares during the last quarter. Choreo LLC purchased a new stake in Sanofi in the second quarter valued at approximately $2,772,000. Wedbush Securities Inc. lifted its stake in Sanofi by 32.9% in the second quarter. Wedbush Securities Inc. now owns 17,068 shares of the company’s stock valued at $828,000 after buying an additional 4,225 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in Sanofi in the second quarter valued at approximately $51,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the topic of a number of recent research reports. Argus boosted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $57.50.

Sanofi Trading Up 0.7 %

NASDAQ:SNY opened at $57.13 on Friday. The stock’s 50 day simple moving average is $53.67 and its 200-day simple moving average is $50.15. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The firm has a market cap of $144.69 billion, a P/E ratio of 28.71, a PEG ratio of 1.63 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts anticipate that Sanofi will post 4.23 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.